Chunghwa Chemical Synthesis & Biotech Co Ltd (CCSB, 中化合成生技) yesterday said that it is ready to produce remdesivir, an experimental antiviral drug being studied as a treatment for COVID-19, if the government determines that it is safe and effective against the novel coronavirus that causes the disease.
The company earlier this week completed the synthesis of 4.73g of remdesivir with a purity of 99.72 percent.
“We spent about two weeks replicating the drug. The synthesis part was not time-consuming, but we spent some time waiting for ingredients from abroad,” CCSB spokesman Eason Wang (王冠傑) told the Taipei Times by telephone.
The company purchased the processed ingredients from overseas, as it lacks low-temperature equipment to proceed with synthesis, he said.
“As some chemical reactions have to take place at a very low temperature — about minus-78°C — when combining the compounds to make remdesivir, a special device is necessary,” Wang said, adding that the firm is considering buying such equipment to enable full production.
CCSB, a manufacturer of active pharmaceutical ingredients, was the latest local institution or company to succeed in replicating the experimental drug after Academia Sinica and Formosa Laboratories Inc (台耀化學).
Remdesivir, developed by US-based Gilead Sciences Inc, has shown promising results in fighting the novel coronavirus in an early analysis of overseas studies, Wang said.
Taiwan is also conducting clinical trials to test the drug’s efficacy, he said.
As no definitive conclusion on whether remdesivir is an effective treatment for COVID-19 has been made and Gilead has a patent for the drug, CCSB does not plan to mass-produce it, unless the government makes it compulsory for local companies to produce such drugs, Wang said.
With a stable supply of ingredients from overseas, CCSB could manufacture 30kg of remdesivir within 12 weeks, which should be enough to treat 30,000 patients, who would each need about 1.1g, he said.
“As the spread of COVID-19 seems to have abated in Taiwan,” with the Central Epidemic Command Center yesterday reporting zero new cases for the third time this week, “we do not expect high demand for the drug domestically,” Wang said.
However, local regulators might consider allowing companies to produce the drug to help other nations deal with escalating outbreaks of the disease, as the government earlier this month donated masks to affected countries, he said.
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said second-quarter revenue is expected to surpass the first quarter, which rose 30 percent year-on-year to NT$118.92 billion (US$3.71 billion). Revenue this quarter is likely to grow, as US clients have front-loaded orders ahead of US President Donald Trump’s planned tariffs on Taiwanese goods, Delta chairman Ping Cheng (鄭平) said at an earnings conference in Taipei, referring to the 90-day pause in tariff implementation Trump announced on April 9. While situations in the third and fourth quarters remain unclear, “We will not halt our long-term deployments and do not plan to
‘SHORT TERM’: The local currency would likely remain strong in the near term, driven by anticipated US trade pressure, capital inflows and expectations of a US Fed rate cut The US dollar is expected to fall below NT$30 in the near term, as traders anticipate increased pressure from Washington for Taiwan to allow the New Taiwan dollar to appreciate, Cathay United Bank (國泰世華銀行) chief economist Lin Chi-chao (林啟超) said. Following a sharp drop in the greenback against the NT dollar on Friday, Lin told the Central News Agency that the local currency is likely to remain strong in the short term, driven in part by market psychology surrounding anticipated US policy pressure. On Friday, the US dollar fell NT$0.953, or 3.07 percent, closing at NT$31.064 — its lowest level since Jan.
The US dollar was trading at NT$29.7 at 10am today on the Taipei Foreign Exchange, as the New Taiwan dollar gained NT$1.364 from the previous close last week. The NT dollar continued to rise today, after surging 3.07 percent on Friday. After opening at NT$30.91, the NT dollar gained more than NT$1 in just 15 minutes, briefly passing the NT$30 mark. Before the US Department of the Treasury's semi-annual currency report came out, expectations that the NT dollar would keep rising were already building. The NT dollar on Friday closed at NT$31.064, up by NT$0.953 — a 3.07 percent single-day gain. Today,
The New Taiwan dollar and Taiwanese stocks surged on signs that trade tensions between the world’s top two economies might start easing and as US tech earnings boosted the outlook of the nation’s semiconductor exports. The NT dollar strengthened as much as 3.8 percent versus the US dollar to 30.815, the biggest intraday gain since January 2011, closing at NT$31.064. The benchmark TAIEX jumped 2.73 percent to outperform the region’s equity gauges. Outlook for global trade improved after China said it is assessing possible trade talks with the US, providing a boost for the nation’s currency and shares. As the NT dollar
RSS